Convenient Preparation of [68Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy

Molecular Imaging and Biology

Volumn 18, Issue 3, 2016, Pages 420-427

  Satpati, Drishty ^a   Shinto, Ajit ^b   Kamaleshwaran, K K ^b   Sane, Surekha ^a   Banerjee, Sharmila ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b KOVAI MEDICAL CENTER AND HOSPITAL   (India)

Author keywords

Freeze dried kits; PET CT; Prostate cancer; Prostate specific membrane antigen (PSMA); 68Ga DKFZ PSMA 11

Indexed keywords

DKFZ PROSTATE SPECIFIC MEMBRANE ANTIGEN 11 GA 68; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG; 68GA-DKFZ-PSMA-11; DIAGNOSTIC KIT; GALLIUM; ORGANOMETALLIC COMPOUND; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; MALE; ORCHIECTOMY; PAPER CHROMATOGRAPHY; PET-CT SCANNER; PH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOCHEMISTRY; CHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC KIT; METABOLISM; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; SYNTHESIS;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GALLIUM RADIOISOTOPES; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REAGENT KITS, DIAGNOSTIC;

EID: 84961201985     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-016-0943-z     Document Type: Article

References (33)

1. Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
2. Perner S, Hofer MD, Kim R et al (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701
3. Apolo AB, Pandit-Taskar N, Morris MJ (2008) Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 49:2031–2041
4. Hillier SM, Maresca KP, Femia FJ et al (2009) Preclinical evaluation of novel glutamate urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 69:6932–6940
5. Maresca KP, Hillier SM, Femia FJ et al (2009) A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 52:347–357
6. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem 57:2657–2669
7. Szabo Z, Mena E, Rowe SP et al (2015) Initial evaluation of [F]DCFPyL for prostate specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 17:565–574
8. 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem 56:6108–6121
9. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med 55:1791–1798
10. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 54:1369–1376
11. Barrett JA, Coleman RE, Goldsmith SJ et al (2013) First-in-man evaluation of two high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 54:380–387
12. 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41:887–897
13. 68Ga]gallium labeled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495
14. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209
15. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674
16. Sanchez-Crespo A, Andreo P, Larsson SA (2004) Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 31:44–51
17. 68Ga-based radiopharmaceuticals: production and application relationship. Molecules 20:12913–12943
18. 68Ga-radiopharmaceutical development. Theranostics 4(1):47–80
19. Morgat C, Hindie E, Mishra AK et al (2013) Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways. Cancer Biother Radiopharm 28(2):85–97
20. Price EW, Orvig C (2014) Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev 43:260–290
21. 68Ga generator integrated system: elution-purification-concentration integration. Recent Results Cancer Res 194:43–75
22. 68Ga generators: past, present, and future. Appl Radiat Isot 76:24–30
23. 68Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use. EJNMMI Res 5:27–34
24. 3 integrin expression and facile radiosynthesis. J Nucl Med 52:1276–1284
25. 68Ga generator integrated system: elution-purification-concentration integration. In: Theranostics, gallium-68, and other radionuclides: a pathway to personalized diagnosis and treatment. In: Baum RP, Rösch F (eds) Springer Science and Business Media pp 43-76
26. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals 7:779–796
27. Joshi BP, Wang TD (2010) Exogenous molecular probes for targeted imaging in cancer: focus on multi-modal imaging. Cancers 2:1251–1287
28. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99:2235–2268
29. James ML, Gambhir SS (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92:897–965
30. 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules 20(8):14860–14878
31. 68Ga-PSMA PET/CT for recurrence detection of prostate cancer. EANM Congress, Hamburg, Germany 2015 - Abstract 697
32. 68Ga generator. J Nucl Med 56(Suppl 3):445
33. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals 7(7):779–796